Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer.

AIMS: To investigate the association between immunohistochemical expression of Bcl-2 and p53 in colorectal cancer and tumour recurrence following surgery. METHODS: Sixty six cases of Dukes' B colorectal carcinoma were studied. All tumours were moderately differentiated and were shown to be hist...

Full description

Bibliographic Details
Main Authors: Ilyas, M, Hao, X, Wilkinson, K, Tomlinson, I, Abbasi, A, Forbes, A, Bodmer, W, Talbot, I
Format: Journal article
Language:English
Published: 1998
_version_ 1826271174653378560
author Ilyas, M
Hao, X
Wilkinson, K
Tomlinson, I
Abbasi, A
Forbes, A
Bodmer, W
Talbot, I
author_facet Ilyas, M
Hao, X
Wilkinson, K
Tomlinson, I
Abbasi, A
Forbes, A
Bodmer, W
Talbot, I
author_sort Ilyas, M
collection OXFORD
description AIMS: To investigate the association between immunohistochemical expression of Bcl-2 and p53 in colorectal cancer and tumour recurrence following surgery. METHODS: Sixty six cases of Dukes' B colorectal carcinoma were studied. All tumours were moderately differentiated and were shown to be histologically clear of the resection margins. Immunohistochemistry was performed on formalin fixed paraffin wax embedded tissue using monoclonal antibodies for p53 and Bcl-2. The Bcl-2 staining was assessed separately for relative intensity of staining and percentage of positive tumour cells and given a final score which combined the two factors. The p53 staining was assessed on number of positive tumour cells only. The patterns of immunostaining of those cases in which there had been tumour recurrence were compared with those cases in which there was no tumour recurrence (controls). RESULTS: A statistically significant inverse association was found between Bcl-2 score and tumour recurrence (median Bcl-2 score of 6 (interquartile range (IQR) 2-9) in patients with recurrent disease; median Bcl-2 score of 8 (IQR 6-10) in those without recurrence; p = 0.03). When examined separately, both the intensity of expression and percentage of positive tumour cells were significantly associated with tumour recurrence (p = 0.04 in each case). There was no association between p53 staining and tumour recurrence. CONCLUSION: Results suggest that, when controlled for differentiation, Bcl-2 expression is a prognostic marker and may be useful as an adjunctive test in clinical decision making.
first_indexed 2024-03-06T21:52:30Z
format Journal article
id oxford-uuid:4bc910b9-2ee5-4651-b0b2-ca39e99ddee8
institution University of Oxford
language English
last_indexed 2024-03-06T21:52:30Z
publishDate 1998
record_format dspace
spelling oxford-uuid:4bc910b9-2ee5-4651-b0b2-ca39e99ddee82022-03-26T15:45:38ZLoss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4bc910b9-2ee5-4651-b0b2-ca39e99ddee8EnglishSymplectic Elements at Oxford1998Ilyas, MHao, XWilkinson, KTomlinson, IAbbasi, AForbes, ABodmer, WTalbot, IAIMS: To investigate the association between immunohistochemical expression of Bcl-2 and p53 in colorectal cancer and tumour recurrence following surgery. METHODS: Sixty six cases of Dukes' B colorectal carcinoma were studied. All tumours were moderately differentiated and were shown to be histologically clear of the resection margins. Immunohistochemistry was performed on formalin fixed paraffin wax embedded tissue using monoclonal antibodies for p53 and Bcl-2. The Bcl-2 staining was assessed separately for relative intensity of staining and percentage of positive tumour cells and given a final score which combined the two factors. The p53 staining was assessed on number of positive tumour cells only. The patterns of immunostaining of those cases in which there had been tumour recurrence were compared with those cases in which there was no tumour recurrence (controls). RESULTS: A statistically significant inverse association was found between Bcl-2 score and tumour recurrence (median Bcl-2 score of 6 (interquartile range (IQR) 2-9) in patients with recurrent disease; median Bcl-2 score of 8 (IQR 6-10) in those without recurrence; p = 0.03). When examined separately, both the intensity of expression and percentage of positive tumour cells were significantly associated with tumour recurrence (p = 0.04 in each case). There was no association between p53 staining and tumour recurrence. CONCLUSION: Results suggest that, when controlled for differentiation, Bcl-2 expression is a prognostic marker and may be useful as an adjunctive test in clinical decision making.
spellingShingle Ilyas, M
Hao, X
Wilkinson, K
Tomlinson, I
Abbasi, A
Forbes, A
Bodmer, W
Talbot, I
Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer.
title Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer.
title_full Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer.
title_fullStr Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer.
title_full_unstemmed Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer.
title_short Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer.
title_sort loss of bcl 2 expression correlates with tumour recurrence in colorectal cancer
work_keys_str_mv AT ilyasm lossofbcl2expressioncorrelateswithtumourrecurrenceincolorectalcancer
AT haox lossofbcl2expressioncorrelateswithtumourrecurrenceincolorectalcancer
AT wilkinsonk lossofbcl2expressioncorrelateswithtumourrecurrenceincolorectalcancer
AT tomlinsoni lossofbcl2expressioncorrelateswithtumourrecurrenceincolorectalcancer
AT abbasia lossofbcl2expressioncorrelateswithtumourrecurrenceincolorectalcancer
AT forbesa lossofbcl2expressioncorrelateswithtumourrecurrenceincolorectalcancer
AT bodmerw lossofbcl2expressioncorrelateswithtumourrecurrenceincolorectalcancer
AT talboti lossofbcl2expressioncorrelateswithtumourrecurrenceincolorectalcancer